Evidence map›Paper›PMID 40993243›Full record

ArticleNature medicine2025

Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

Jingjing Feng, Dawei Huo, Ruimin Hong, Xuexiao Jin, Heng Cao, Mi Shao, Rui Wen, Qiqi Zhang, Mingming Zhang, Shan Fu and 12 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Anti-CD19-engineered exosomes enable B cell-targeted anti-BAFF mRNA delivery to alleviate lupus progression.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jingjing Feng *Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Dawei Huo *Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ruimin Hong *Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xuexiao Jin *Institute of Immunology and Department of Rheumatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0001-5402-5623
Heng Cao *Department of Rheumatology of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Mi Shao *Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Rui Wen *Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qiqi ZhangBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Mingming ZhangBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shan FuBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Dongrui WangBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Huijun XuBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Guoqing WeiBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiazhen CuiBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Simao HuangBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Dawei CuiDepartment of Blood Transfusion of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Alex Hongsheng ChangEngineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China. changah@yakebiotech.com.ORCID http://orcid.org/0000-0002-7572-309X
Zhihong LiuLiangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China. liuzhihong@zju.edu.cn.ORCID http://orcid.org/0000-0001-6093-0726
Linrong LuInstitute of Immunology and Department of Rheumatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. lu_linrong@zju.edu.cn.ORCID http://orcid.org/0000-0002-0171-4115
Jin LinDepartment of Rheumatology of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. linjinzju@zju.edu.cn.ORCID http://orcid.org/0000-0002-9970-9380
Yongxian HuBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 1313016@zju.edu.cn.ORCID http://orcid.org/0000-0001-9564-1852
He HuangBone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. huanghe@zju.edu.cn.ORCID http://orcid.org/0000-0002-2723-1621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) remains refractory to conventional immunosuppression in a subset of patients. In treatment-refractory SLE, we show that peripheral CD19

Indexed as

Antigens, CD19B-Cell Maturation AntigenImmunotherapy, AdoptiveLupus Erythematosus, SystemicReceptors, Chimeric AntigenT-LymphocytesAdultAutoantibodiesB-LymphocytesCyclophosphamideFemaleHumansMaleMiddle AgedTreatment OutcomeVidarabineAntigens, CD19AutoantibodiesB-Cell Maturation AntigenCyclophosphamidefludarabineReceptors, Chimeric AntigenVidarabine

Identifiers

PMID40993243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.